Zhan Yiyi, Abuduwaili Kahaerjiang, Wang Xiuli, Shen Yanli, Nuerlan Saiteer, Liu Chunling
The Second Department of Pulmonary Medicine, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Cancer Manag Res. 2020 Aug 24;12:7725-7737. doi: 10.2147/CMAR.S246299. eCollection 2020.
Long non-coding RNA (lncRNA) has been reported to be associated with cisplatin (DDP) resistance in different human cancers including non-small cell lung cancer (NSCLC). However, the mechanism of HOTAIR in cisplatin resistance of NSCLC remains largely undefined.
Expression of , and () was detected using real-time quantitative PCR (RT-qPCR) and Western blotting. Cisplatin resistance was determined with cell counting kit (CCK)-8 assay and transwell assays in vitro, and xenograft tumor models in vivo. The target binding between and either or was predicted on Diana Tools website, and confirmed by dual-luciferase reporter assay and RNA immunoprecipitation.
Expression of was upregulated in DDP-resistant NSCLC tumor tissues and cell lines (A549/DDP and H1299/DDP). Knockdown of decreased the acquired cisplatin resistance of A549/DDP and H1299/DDP cells, as evidenced by attenuated 50% inhibitory concentration (IC50) of DDP, cell proliferation, migration and invasion in vitro, as well as tumor growth inhibition in vivo. Mechanically, negatively regulated expression via targeting, and DCLK1 was a downstream target for miR-149-5p. was indirectly regulated by in DDP-resistant NSCLC cells as well. Functionally, deletion could counteract the inhibitory effect of HOTAIR knockdown on cisplatin resistance; contrarily, restoring exhibited the similar inhibition on cisplatin resistance in DDP-resistant cells in vitro, which was then abated by upregulation.
Knockdown of enhances DDP-resistant NSCLC cells to overcome cisplatin resistance partially via regulating / axis.
长链非编码RNA(lncRNA)已被报道与包括非小细胞肺癌(NSCLC)在内的不同人类癌症中的顺铂(DDP)耐药性相关。然而,HOTAIR在NSCLC顺铂耐药中的机制仍不清楚。
采用实时定量PCR(RT-qPCR)和蛋白质免疫印迹法检测 、 和 ()的表达。用细胞计数试剂盒(CCK)-8法和体外Transwell实验以及体内异种移植瘤模型测定顺铂耐药性。在Diana Tools网站上预测 与 或 之间的靶标结合,并通过双荧光素酶报告基因实验和RNA免疫沉淀法进行验证。
在DDP耐药的NSCLC肿瘤组织和细胞系(A549/DDP和H1299/DDP)中表达上调。敲低 可降低A549/DDP和H1299/DDP细胞获得性顺铂耐药性,表现为DDP的50%抑制浓度(IC50)降低、体外细胞增殖、迁移和侵袭减弱以及体内肿瘤生长抑制。机制上, 通过靶向负调控 表达,且DCLK1是miR-149-5p的下游靶标。在DDP耐药的NSCLC细胞中, 也间接受 调控。功能上, 缺失可抵消HOTAIR敲低对顺铂耐药性的抑制作用;相反,恢复 在体外对DDP耐药细胞的顺铂耐药性表现出类似的抑制作用,而这种作用随后被 上调所减弱。
敲低 通过调节 / 轴部分增强DDP耐药的NSCLC细胞克服顺铂耐药性的能力。